SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation to investors attending the Stifel Nicolaus Healthcare Conference on Wednesday, September 15 at 8:35 a.m. ET at the Four Seasons Hotel in Boston, MA. A live webcast will be available through the Investor Relations page of the Trius website at http://investor.triusrx.com. A webcast replay will be available approximately two hours after the presentation and will be archived for 30 days. About Trius Therapeutics Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit www.triusrx.com. SOURCE Trius Therapeutics, Inc.